Rising to the challenges of rare disease treatmentWe are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Specialized BioTherapeutics Pipeline
Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|---|---|---|---|
| SGX301 for Cutaneous T-Cell Lymphoma (CTCL) | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| SGX942 for Oral Mucositis | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| SGX203 for Pediatric Crohn’s Disease | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| SGX201 for Radiation Enteritis | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
Orphan and/or Fast Track Designation
Denotes funding by NIH, BARDA, DTRA and/or FDA.
Public Health Solutions Pipeline
Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.
| Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
|---|---|---|---|---|
| RiVax® to Prevent Ricin Poisoning | ||||
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
| SGX943 for Infectious Disease | ||||
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
| ThermoVax®: Thermostabilized Vaccines for Global Use | ||||
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
Orphan and/or Fast Track Designation
Denotes funding by NIH, BARDA, DTRA and/or FDA.
The Latest
Resources
News
Frontiers in Immunity CoVaccine HT™ Publication
CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARSCoV- 2 Spike S1 Immunization
External Link
Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…